|
Parameters
|
All patients
|
Normal ALT
|
High ALT
|
P
|
|---|
|
N (%)
|
105 (100%)
|
57 (54.3%)
|
48 (45.7%)
| |
|
Female
|
56 (53.3%)
|
33 (57.9%)
|
23 (47.9%)
|
0.307
|
|
Age (years)
|
51.1 ± 11.2
|
52.9 ± 9.4
|
49.1 ± 12.8
|
0.079
|
|
Height (m)
|
1.7 ± 0.1
|
1.7 ± 0.1
|
1.7 ± 0.1
|
0.502
|
|
Weight (kg)
|
144.0 ± 27.6
|
145.2 ± 27.3
|
142.6 ± 28.2
|
0.627
|
|
BMI (kg m2)
|
50.6 ± 8.0
|
51.5 ± 8.2
|
49.7 ± 8.0
|
0.254
|
|
EBW%
|
102.5 ± 32.0
|
106.0 ± 33.0
|
98.6 ± 31.2
|
0.254
|
|
ALTa (iu/L)
|
28.0 [20.0,40.5]
|
22.0 [17.0,24.5]
|
41.5 [34.3,63.5]
|
< 0.0005
|
|
Total cholesterol (mmol/L)
|
4.6 ± 1.0
|
4.6 ± 1.0
|
4.6 ± 1.0
|
0.786
|
|
LDL (mmol/L)
|
2.5 ± 0.9
|
2.5 ± 0.9
|
2.6 ± 0.8
|
0.442
|
|
HDL (mmol/L)
|
1.2 ± 0.4
|
1.3 ± 0.4
|
1.2 ± 0.4
|
0.131
|
|
Triglyceride (mmol/L)
|
1.8 ± 0.8
|
1.7 ± 0.6
|
1.9 ± 1.0
|
0.151
|
|
Diabetes
|
37 (35.2%)
|
19 (33.3%)
|
18 (37.5%)
|
0.656
|
|
HbA1c (mmol/mol)
|
48.2 ± 15.6
|
48.1 ± 16.3
|
48.4 ± 15.0
|
0.943
|
|
Medications
|
|
Metformin
|
38 (36.2%)
|
22 (38.6%)
|
16 (33.3%)
|
0.576
|
|
Insulin
|
10 (9.5%)
|
7 (12.3%)
|
3 (6.3%)
|
0.294
|
|
SU
|
15 (14.3%)
|
10 (17.5%)
|
5 (10.4%)
|
0.298
|
|
DPP4
|
9 (8.6%)
|
6 (10.5%)
|
3 (6.3%)
|
0.436
|
|
SGLT2
|
6 (5.7%)
|
3 (5.3%)
|
3 (6.3%)
|
0.828
|
|
GLP1
|
18 (17.1%)
|
9 (15.8%)
|
9 (18.8%)
|
0.688
|
|
PPARG
|
1 (1%)
|
1 (1.8%)
|
–
|
0.356
|
|
ARBs
|
25 (23.8%)
|
12 (21.1%)
|
13 (27.1%)
|
0.470
|
|
ACEIs
|
30 (28.6%)
|
19 (33.3%)
|
11 (22.9%)
|
0.239
|
|
Beta blockers
|
31 (29.5%)
|
17 (29.8%)
|
14(29.2%)
|
0.914
|
|
Alpha blockers
|
6 (5.7%)
|
3 (5.3%)
|
3 (6.3%)
|
0.828
|
|
Diuretics
|
31 (29.5%)
|
15 (26.3%)
|
16 (33.3%)
|
0.432
|
|
Ezetemibe
|
4 (3.8%)
|
2 (3.4%)
|
2 (4.2%)
|
0.861
|
- Values are presented as Mean ± SD
- Comparisons between groups were made using Independent samples t test for normally distributed data, and Mann–Whitney U test for non-normally distributed data
- Proportions with categorical variables were compared using Pearson’s Chi-square test
- BMI Body Mass Index, EBW% Excess Body Weight Percentage, ALT Alanine Aminotransferase, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, HbA1c Glycated haemoglobin, SU Sulfonylureas, DDP4 Dipeptidyl peptidase-4 inhibitors, SGLT2 Sodium-glucose co-transporter 2 inhibitors, GLP1 Glucagon-like peptide 1, PPARG Peroxisome proliferator-activated receptor gamma, ARBs Angiotensin II receptor blockers, ACEIs Angiotensin-converting enzyme inhibitors
- aDenotes variables that are not normally distributed, presented as median [IQR]
